KBC Group NV Has $89.87 Million Holdings in Pfizer Inc. (NYSE:PFE)

KBC Group NV raised its holdings in Pfizer Inc. (NYSE:PFE) by 26.0% in the third quarter, Holdings Channel reports. The fund owned 3,105,433 shares of the biopharmaceutical company’s stock after acquiring an additional 639,985 shares during the period. KBC Group NV’s holdings in Pfizer were worth $89,872,000 at the end of the most recent quarter.

A number of other hedge funds also recently modified their holdings of PFE. Addison Advisors LLC lifted its stake in Pfizer by 394.2% in the third quarter. Addison Advisors LLC now owns 52,238 shares of the biopharmaceutical company’s stock valued at $1,512,000 after buying an additional 41,668 shares in the last quarter. Sumitomo Mitsui Trust Group Inc. boosted its stake in Pfizer by 4.3% in the 3rd quarter. Sumitomo Mitsui Trust Group Inc. now owns 13,118,764 shares of the biopharmaceutical company’s stock worth $379,657,000 after purchasing an additional 544,418 shares during the period. LGT Group Foundation increased its holdings in Pfizer by 2.5% during the 2nd quarter. LGT Group Foundation now owns 742,875 shares of the biopharmaceutical company’s stock worth $20,786,000 after purchasing an additional 18,274 shares in the last quarter. Radnor Capital Management LLC acquired a new stake in shares of Pfizer in the 3rd quarter valued at about $2,972,000. Finally, Kornitzer Capital Management Inc. KS lifted its holdings in shares of Pfizer by 2.4% in the third quarter. Kornitzer Capital Management Inc. KS now owns 1,168,315 shares of the biopharmaceutical company’s stock valued at $33,811,000 after purchasing an additional 27,562 shares in the last quarter. Institutional investors and hedge funds own 68.36% of the company’s stock.

Insider Transactions at Pfizer

In other Pfizer news, Director Scott Gottlieb acquired 1,000 shares of Pfizer stock in a transaction that occurred on Wednesday, October 30th. The shares were acquired at an average cost of $28.24 per share, with a total value of $28,240.00. Following the completion of the purchase, the director now directly owns 10,000 shares of the company’s stock, valued at $282,400. This represents a 0.00 % increase in their position. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. 0.06% of the stock is owned by insiders.

Pfizer Stock Performance

NYSE:PFE opened at $26.72 on Thursday. The company has a debt-to-equity ratio of 0.63, a quick ratio of 0.73 and a current ratio of 1.00. Pfizer Inc. has a fifty-two week low of $25.20 and a fifty-two week high of $31.54. The company has a market cap of $151.42 billion, a price-to-earnings ratio of 36.11, a PEG ratio of 0.83 and a beta of 0.67. The stock has a fifty day moving average price of $28.80 and a 200-day moving average price of $28.68.

Pfizer (NYSE:PFE) last issued its earnings results on Tuesday, October 29th. The biopharmaceutical company reported $1.06 EPS for the quarter, beating the consensus estimate of $0.64 by $0.42. The company had revenue of $17.70 billion during the quarter, compared to analysts’ expectations of $14.92 billion. Pfizer had a net margin of 7.07% and a return on equity of 16.28%. The business’s revenue for the quarter was up 31.2% compared to the same quarter last year. During the same period in the previous year, the company earned ($0.17) EPS. As a group, equities analysts anticipate that Pfizer Inc. will post 2.96 EPS for the current fiscal year.

Pfizer Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Monday, December 2nd. Stockholders of record on Friday, November 8th will be paid a $0.42 dividend. The ex-dividend date is Friday, November 8th. This represents a $1.68 annualized dividend and a dividend yield of 6.29%. Pfizer’s payout ratio is 227.03%.

Analyst Upgrades and Downgrades

Several equities research analysts have issued reports on PFE shares. UBS Group lifted their price target on shares of Pfizer from $30.00 to $31.00 and gave the company a “neutral” rating in a research note on Wednesday, July 31st. Wells Fargo & Company upped their target price on Pfizer from $28.00 to $30.00 and gave the stock an “equal weight” rating in a report on Wednesday, July 31st. Evercore ISI upgraded Pfizer to a “strong-buy” rating in a research note on Wednesday, October 30th. Cantor Fitzgerald reiterated an “overweight” rating and set a $45.00 price objective on shares of Pfizer in a research note on Wednesday, October 23rd. Finally, StockNews.com raised shares of Pfizer from a “buy” rating to a “strong-buy” rating in a research note on Tuesday. Eight equities research analysts have rated the stock with a hold rating, five have given a buy rating and three have issued a strong buy rating to the company’s stock. Based on data from MarketBeat, Pfizer presently has an average rating of “Moderate Buy” and an average target price of $33.58.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.